Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L M Jost

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2005
ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patientsM F Fey, R Greil, L M Jost, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2005
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphomaL M Jost, O Kloke, R A Stahel, et al.
Schweizerische Medizinische Wochenschrift|February 23, 2000
[High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich]L M Jost, H P Honegger, R A Stahel
Journal of Immunological Methods|March 4, 1992
Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cellsL M Jost, J M Kirkwood, T L Whiteside
Critical Reviews in Oncology/Hematology|January 1, 1992
Tumor-infiltrating lymphocytes. Potential and limitations to their use for cancer therapyT L Whiteside, L M Jost, R B Herberman
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2005
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancerD Cunningham, L M Jost, G Purkalne, et al.
Oncology|September 6, 2000
Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center studyG Tscherry, E Jacky, L M Jost, et al.
British Journal of Cancer|February 1, 1991
Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanomaG Pichert, L M Jost, W Fierz, et al.
Cancer Treatment Reviews|January 1, 1995
High-dose chemotherapy and autologous bone marrow transplantation for malignant lymphomasR A Stahel, L M Jost, G Pichert, et al.
Blood|October 15, 1996
Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cellsL Widmer, G Pichert, L M Jost, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2005
ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patientsM F Fey, R Greil, L M Jost, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2005
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin's lymphomaL M Jost, O Kloke, R A Stahel, et al.
Schweizerische Medizinische Wochenschrift|February 23, 2000
[High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich]L M Jost, H P Honegger, R A Stahel
Journal of Immunological Methods|March 4, 1992
Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cellsL M Jost, J M Kirkwood, T L Whiteside
Critical Reviews in Oncology/Hematology|January 1, 1992
Tumor-infiltrating lymphocytes. Potential and limitations to their use for cancer therapyT L Whiteside, L M Jost, R B Herberman
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2005
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancerD Cunningham, L M Jost, G Purkalne, et al.
Oncology|September 6, 2000
Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center studyG Tscherry, E Jacky, L M Jost, et al.
British Journal of Cancer|February 1, 1991
Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanomaG Pichert, L M Jost, W Fierz, et al.
Cancer Treatment Reviews|January 1, 1995
High-dose chemotherapy and autologous bone marrow transplantation for malignant lymphomasR A Stahel, L M Jost, G Pichert, et al.
Blood|October 15, 1996
Fate of contaminating t(14; 18)+ lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cellsL Widmer, G Pichert, L M Jost, et al.
Pageof 4